Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

Breast Cancer Clinical Trial

Official title:

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxanes-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06199895
• Other study ID #: PM1
• Status: Recruiting
• Phase: Phase 2
• Start date: November 28, 2023
• Est. completion date: November 2025

Study information

• Verified date: December 2023
• Source: Tongji Hospital
• Contact: Liu Huang
• Phone: 63639656
• Email: huangliu[@]tjh.tjmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single-center, single-arm, open-label, phase II clinical trial designed to evaluate the efficacy and safety of Paclitaxel Polymeric Micelles for Injection for the treatment of patients with advanced pancreatic adenocarcinoma, cholangiocarcinoma, lung cancer, gastric cancer, esophageal carcinoma, or breast cancer that are resistant to Taxanes.

Subjects are given paclitaxel polymeric micelles for injection, three weeks constitutes one cycle of treatment.

If subject does not develop disease progression , the subject continues treatment until disease progression (RECIST 1.1) or develops an intolerable toxicity, initiation of a new anti-cancer drug, withdrawal from the study, death, or loss of follow-up.

This is a single-arm, small-sample clinical study with the primary efficacy goal of objective remission rate (ORR). The parameters of the trial were set: assuming a class I error of 0.025 unilaterally, power=90%, and a 15% improvement in ORR for objective remission rate, a total of 20 subjects would be required, and a total of 25 would be required for enrolment, taking into account a 20% shedding.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: November 2025
• Est. primary completion date: November 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1.Male or female 18 years and older; 2.Patients with advanced pancreatic adenocarcinoma, cholangiocarcinoma, lung cancer, gastric cancer, esophageal carcinoma, or breast cancer diagnosed by histological or cytological pathology; must have an evaluable lesion; 3.Previous treatment regimen includes Taxanes and is resistant to Taxanes (including patients with initial failure to remit or progression after remission) or previous use of Taxanes for at least 2 cycles without tumour shrinkage and the patient is not satisfied with current stable efficacy and is willing to be enrolled in this study; 4.ECOG (Eastern Cooperative Oncology Group) score = 2 points; 5.expected survival of at least 3 months; 6.Blood routine examination meets the following criteria:

1. WBC=3.0×109 /L,ANC=1.5×109 /L;

2. PLT=100×109 /L;

3. Hb=80g/L; 7.Blood biochemical examination must meet the following criteria:

1. Total bilirubin =1.5 times the upper limit of normal (ULN);

2. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) =2.5 times ULN (ALT, AST, or ALP= 5×ULN for subjects with liver metastases, and ALP=10×ULN for subjects with bone metastases);

3. Creatinine clearance (calculated using Cockcroft-Gault formula) =50 ml/min; 8.Functions of major organs such as heart, lung, liver and kidney are basically normal; 9.Subjects have good compliance and voluntarily comply with the clinical trial protocol during the study, followed up by the investigators; 10.All women of childbearing age, men of childbearing potential, or their spouses who have no plans to have children or donate sperm during the entire trial period and up to 6 months after the last dose of medication, or who voluntarily used effective contraception; Women of childbearing age who have a negative blood/urine pregnancy test within 7 days prior to enrollment; 11.Subjects had fully understood the study and voluntarily signed the informed consent form .

Exclusion Criteria:

• 1.Subjects with an allergic history to experimental drugs or any excipients; 2.Subjects with acute or chronic infections that have not been eliminated, or subjects with other serious diseases at the same time; 3.Subjects with active hepatitis and uncontrolled by antiviral therapy, or liver metastasis is more than 3/4 of the whole liver; 4.Subjects with third-space effusions (e.g., moderate-to-massive pleural effusion, moderate-to-massive pericardial effusion, ascites) that cannot be controlled by drainage or other means; 5.Subjects with mental illness or disorder, poor compliance, or inability to cooperate, or describe treatment responses; 6.Subjects who cannot tolerate chemotherapy due to severe organic disease or major organ failure, such as decompensated heart and lung failure; 7.Subjects with bleeding disorders; 8.Subjects with organ transplant; 9.Subjects with bad drug addicts, long-term alcoholics, infectious diseases such as AIDS; 10.Subjects who still have grade =2 toxicity from previous antineoplastic therapy (except alopecia and grade =2 neurotoxicity caused by platinum) at enrollment; 11.Subjects are considered not able to complete the trial or otherwise unfit to participate in the study by the investigators.

Related Conditions & MeSH terms

• Adenocarcinoma
• Breast Cancer
• Breast Neoplasms
• Carcinoma
• Cholangiocarcinoma
• Esophageal Carcinoma
• Esophageal Neoplasms
• Lung Cancer
• Lung Neoplasms
• Pancreatic Adenocarcinoma
• Stomach Cancer
• Stomach Neoplasms

Intervention

Drug:
• Paclitaxel Polymeric Micelles for Injection
300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for = 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.

Locations

Country	Name	City	State
China	Tongji Hospital	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Liu Huang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate	Proportion of subjects who have achieved complete response (CR) or partial response (PR) (RECIST 1.1)	Baseline to measured PD(up to 24 months)
Secondary	Progression-Free-Survival	PFS(Progression-Free-Survival) was the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurred first.	Randomization to measured PD or date of death from any cause(up to 24 months)]
Secondary	Disease Control Rate	Proportion of subjects who have achieved complete response (CR), partial response (PR) or stable disease (SD) (RECIST 1.1)	Baseline to measured PD(up to 24 months)
Secondary	Overall Survival	The time from randomization to death.	Randomization to date of death from any cause(up to 24 months)]
Secondary	Incidence of adverse events	Safety	up to 24 months